JP2024513921A5 - - Google Patents
Info
- Publication number
- JP2024513921A5 JP2024513921A5 JP2023561755A JP2023561755A JP2024513921A5 JP 2024513921 A5 JP2024513921 A5 JP 2024513921A5 JP 2023561755 A JP2023561755 A JP 2023561755A JP 2023561755 A JP2023561755 A JP 2023561755A JP 2024513921 A5 JP2024513921 A5 JP 2024513921A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- region
- antigen binding
- amino acid
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174772P | 2021-04-14 | 2021-04-14 | |
| US63/174,772 | 2021-04-14 | ||
| US202163279762P | 2021-11-16 | 2021-11-16 | |
| US63/279,762 | 2021-11-16 | ||
| PCT/US2022/024620 WO2022221409A1 (en) | 2021-04-14 | 2022-04-13 | Anti-cd122 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513921A JP2024513921A (ja) | 2024-03-27 |
| JP2024513921A5 true JP2024513921A5 (cg-RX-API-DMAC7.html) | 2025-04-23 |
Family
ID=81579792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561755A Pending JP2024513921A (ja) | 2021-04-14 | 2022-04-13 | 抗ｃｄ１２２抗体及びその使用 |
Country Status (19)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025537224A (ja) * | 2022-11-07 | 2025-11-14 | アナプティスバイオ インコーポレイティッド | Ｃｄ１２２結合剤およびその使用方法 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
-
2022
- 2022-04-13 PH PH1/2023/552784A patent/PH12023552784A1/en unknown
- 2022-04-13 GE GEAP202316382A patent/GEAP202316382A/en unknown
- 2022-04-13 CR CR20230523A patent/CR20230523A/es unknown
- 2022-04-13 GE GEAP202416574A patent/GEAP202416574A/en unknown
- 2022-04-13 JP JP2023561755A patent/JP2024513921A/ja active Pending
- 2022-04-13 WO PCT/US2022/024620 patent/WO2022221409A1/en not_active Ceased
- 2022-04-13 MX MX2023012218A patent/MX2023012218A/es unknown
- 2022-04-13 BR BR112023021297A patent/BR112023021297A2/pt unknown
- 2022-04-13 IL IL307267A patent/IL307267A/en unknown
- 2022-04-13 CA CA3215058A patent/CA3215058A1/en active Pending
- 2022-04-13 KR KR1020237034415A patent/KR20230170672A/ko active Pending
- 2022-04-13 PE PE2023002851A patent/PE20240086A1/es unknown
- 2022-04-13 AU AU2022256455A patent/AU2022256455A1/en active Pending
- 2022-04-13 GE GEAP202216382A patent/GEP20257805B/en unknown
- 2022-04-13 EP EP22720859.2A patent/EP4323402A1/en active Pending
-
2023
- 2023-06-16 US US18/336,478 patent/US20230357420A1/en not_active Abandoned
- 2023-06-16 US US18/336,404 patent/US20230322944A1/en active Pending
- 2023-09-29 DO DO2023000211A patent/DOP2023000211A/es unknown
- 2023-10-11 JO JOJO/P/2023/0246A patent/JOP20230246A1/ar unknown
- 2023-10-12 CL CL2023003048A patent/CL2023003048A1/es unknown
- 2023-11-10 CO CONC2023/0015254A patent/CO2023015254A2/es unknown
- 2023-11-13 EC ECSENADI202385780A patent/ECSP23085780A/es unknown
-
2024
- 2024-09-24 CL CL2024002847A patent/CL2024002847A1/es unknown